SecSonar.com

Nanobiotix S.A. (NBTX)

Nanobiotix S.A. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Nanobiotix S.A. (NBTX) is a Biotechnology company based in FR with a market capitalization of $2B. Revenue grew 512.3% year-over-year and free cash flow was negative at -$38.9M. This page tracks NBTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

FR · 108 employees · IPO Dec 11, 2020

Valuation

Valuation & price

$51.50 · as of May 17, 2026 · -6.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$55.07$29.93$4.79Jul 25Dec 25Jul 26Jul 7, 25$4.79Jul 9, 25$5.34Jul 11, 25$5.17Jul 15, 25$5.33Jul 17, 25$5.30Jul 21, 25$5.11Jul 23, 25$5.80Jul 25, 25$6.81Jul 29, 25$6.95Jul 31, 25$6.90Aug 4, 25$6.80Aug 6, 25$6.90Aug 11, 25$7.35Aug 13, 25$7.85Aug 15, 25$7.91Aug 19, 25$9.00Aug 21, 25$9.74Aug 25, 25$9.85Aug 27, 25$8.99Aug 29, 25$8.95Sep 3, 25$8.66Sep 5, 25$8.70Sep 9, 25$9.14Sep 11, 25$9.95Sep 16, 25$9.74Sep 18, 25$12.31Sep 22, 25$12.86Sep 24, 25$16.44Sep 26, 25$16.24Sep 30, 25$18.89Oct 2, 25$19.88Oct 6, 25$22.78Oct 8, 25$27.30Oct 10, 25$23.60Oct 14, 25$28.23Oct 16, 25$26.57Oct 21, 25$22.62Oct 23, 25$19.28Oct 27, 25$15.08Oct 29, 25$17.99Oct 31, 25$20.87Nov 4, 25$19.33Nov 6, 25$19.67Nov 10, 25$22.17Nov 12, 25$21.58Nov 14, 25$20.80Nov 18, 25$21.80Nov 20, 25$20.38Nov 25, 25$21.23Nov 28, 25$20.69Dec 2, 25$20.49Dec 4, 25$21.82Dec 8, 25$21.03Dec 10, 25$22.54Dec 12, 25$22.70Dec 16, 25$22.32Dec 18, 25$22.10Dec 22, 25$22.88Dec 24, 25$22.65Dec 29, 25$22.49Jan 2, 26$22.13Jan 6, 26$20.37Jan 8, 26$19.97Jan 12, 26$20.07Jan 14, 26$21.53Jan 16, 26$20.99Jan 21, 26$20.06Jan 23, 26$20.94Jan 27, 26$22.53Jan 29, 26$21.89Feb 2, 26$21.37Feb 4, 26$21.73Feb 9, 26$23.57Feb 11, 26$24.12Feb 13, 26$25.34Feb 18, 26$26.82Feb 20, 26$24.78Feb 24, 26$25.45Feb 26, 26$27.51Mar 2, 26$31.96Mar 4, 26$35.93Mar 6, 26$33.99Mar 10, 26$38.65Mar 12, 26$31.52Mar 17, 26$32.08Mar 19, 26$31.61Mar 23, 26$30.54Mar 25, 26$30.63Mar 27, 26$29.95Mar 31, 26$30.87Apr 2, 26$31.04Apr 7, 26$30.14Apr 9, 26$30.59Apr 13, 26$32.00Apr 15, 26$33.20Apr 17, 26$33.79Apr 22, 26$32.20Apr 24, 26$33.58Apr 28, 26$33.12Apr 30, 26$34.62May 4, 26$31.16May 6, 26$41.86May 8, 26$45.49May 12, 26$48.24May 14, 26$55.07May 18, 26$49.48May 20, 26$43.16May 22, 26$41.01May 28, 26$40.41Jun 1, 26$38.00Jun 3, 26$35.20Jun 5, 26$35.46Jun 9, 26$34.34Jun 11, 26$35.33Jun 15, 26$37.12Jun 17, 26$36.07Jun 22, 26$35.23Jun 24, 26$34.35Jun 26, 26$35.99Jul 2, 26$38.40
$4.7952-week range$55.07
Loading valuation history…

Fundamentals

Key fundamentals

$2B

Market cap

512.3%

Revenue growth (YoY)

100.0%

Gross margin

-$38.9M

Free cash flow (USD)

$42.6M

Net debt

1.2%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$5.4MFY 2017$3.7MFY 2018$3.5MFY 2019$2.5MFY 2020$2.3MFY 2021$2.6MFY 2022$4.8MFY 2023$36.2MFY 2024$-7.2MFY 2025$29.6M
$5.4M$29.6M

Free cash flow by year

2016 → 2025

FY 2016$-18.7MFY 2017$-22.3MFY 2018$-26.4MFY 2019$-42.3MFY 2020$-27.6MFY 2021$-30.1MFY 2022$-37.2MFY 2023$-12.8MFY 2024$-20.4MFY 2025$-34.0M
-$18.7M-$34M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 2, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingVoting Rights UpdateJun 5, 2026Filing
  • 6-K filingInclusion in Euronext IndexJun 2, 2026Filing
  • Quarterly reportQuarterly Report FiledJun 2, 2026Filing
  • 6-K filingGlobal Offering ClosedMay 26, 2026Filing
  • 6-K filingCapital RaiseMay 26, 2026Filing
  • 6-K filingCapital RaiseMay 22, 2026Filing
  • 6-K filingGlobal Follow-On OfferingMay 21, 2026Filing
  • 6-K filingTrading HaltMay 21, 2026Filing
  • 6-K filingTrading ResumptionMay 21, 2026Filing
  • 6-K filingGlobal Offering AnnouncementMay 21, 2026Filing

Questions

Frequently asked questions

What is Nanobiotix S.A.'s market cap?

Nanobiotix S.A. (NBTX) has a market capitalization of $2B.

What is NBTX's P/E ratio?

A meaningful P/E ratio is not available for NBTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying NBTX stock?

SEC Form 4 filings show no open-market insider buys at Nanobiotix S.A. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

OCUL

Ocular Therapeutix, Inc.

$2B

ZLAB

Zai Lab Limited

$2B

MESO

Mesoblast Limited

$2B

AUPH

Aurinia Pharmaceuticals Inc.

$2B

CLDX

Celldex Therapeutics, Inc.

$2.1B

IMNM

Immunome, Inc.

$2.1B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.